Connect with us

Hi, what are you looking for?

World News

Sanofi, GSK variant-specific COVID-19 shot found effective against Omicron

PARIS/LONDON: Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday (Jun 24).

The so-called bivalent vaccine targets the Beta variant – first identified in South Africa – as well as the original Wuhan strain of the virus.

In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7 per cent against symptomatic COVID-19, and 72 per cent efficacy against infections specifically caused by the Omicron variant.

When used in people who previously had COVID-19, the results were stronger. The vaccine generated an efficacy rate of 75.1 per cent against symptomatic COVID-19 and 93.2 per cent in Omicron-confirmed symptomatic cases, the companies said.

Advertisement. Scroll to continue reading.

“Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,” Sanofi said in a statement.

Sanofi’s Paris-listed shares and GSK’s London-listed shares were both up more than 1 per cent in morning trading.

Earlier this month, the bivalent vaccine showed potential in two trials to protect against the virus’ main variants of concern – the Omicron BA.1 and BA.2 strains – when used as a booster shot.

Sanofi and GSK, two of the world’s biggest vaccine makers, are hoping to gain a foothold in the market for next-generation variant-focused COVID shots, after falling behind competitors including Moderna, AstraZeneca and Pfizer-BioNTech, in the original race to contain the pandemic.

The new data supporting the bivalent vaccine will be submitted to regulatory authorities with the hope of making the shot available later this year, the companies said on Friday.

Sanofi and GSK’s original COVID-19 vaccine is already under review by the European Medicines Agency.

Advertisement. Scroll to continue reading.

The companies have bet that this bivalent vaccine moulded on the now-supplanted Beta variant will confer broad protection against future viral strains on the basis that Beta expresses similar mutations across multiple variants of concern, including Omicron.

Source link


You May Also Like

World News

For months, cities across China have been placed under full or partial lockdown. Beijing: After a senior Communist Party official said that the “zero-covid”...

US News

MADISON, Wis. (AP) — Wisconsin Democrats looking to unseat Republican Sen. Ron Johnson focused their attacks on him Sunday, and not each other, as...

US News

Dear Amy: This year several people from my past have contacted me to ask for forgiveness. I am writing because I believe my decision...


INDIANAPOLIS (AP) — Manager Ashley Ford strode the perimeter of one of Indianapolis’ five open swimming pools, monitoring kids as they jumped off a...

Science News

WASHINGTON (AP) — President Joe Biden nominated the former head of two federal science and engineering agencies to be his science adviser, who if...

World News

BEIJING: China reported zero new Covid-19 infections in Shanghai for the first time since March on Saturday, as the country’s latest outbreak subsides after...